1-9 of 9
Stephen B Howell, MD
Close
Sort by
Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-141495
Published: 2020
Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141409
Published: 2020
Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5477.
https://doi.org/10.1182/blood-2019-130784
Published: 2019
Journal Articles

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5148.
https://doi.org/10.1182/blood-2019-129685
Published: 2019
Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5755.
https://doi.org/10.1182/blood-2019-123571
Published: 2019
Journal Articles

Mechanisms of Resistance to Apto-253

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, Andrea Local, PhD, William G. Rice, PhD, Stephen B Howell, MD
Journal: Blood
Blood (2016) 128 (22): 5247.
https://doi.org/10.1182/blood.V128.22.5247.5247
Published: 2016
Journal Articles

Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Stephen E. Kurtz, PhD, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, William Rice, PhD, Stephen B Howell, MD, Avanish Vellanki, Brian J. Druker, MD, Jeffrey W. Tyner, PhD
Journal: Blood
Blood (2015) 126 (23): 1358.
https://doi.org/10.1182/blood.V126.23.1358.1358
Published: 2015
Journal Articles

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

William G. Rice, PhD, Jeff Lightfoot, PhD, Hongying Zhang, MD PhD, Tiffany Cheng, MSc, Avanish Vellanki, Robert Peralta, MSc, DVM, Stephen B Howell, MD, Andrea Local, Fannie Chau, Luis Esquivies
Journal: Blood
Blood (2015) 126 (23): 4934.
https://doi.org/10.1182/blood.V126.23.4934.4934
Published: 2015
Journal Articles

A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells

Suping Zhang, PhD, Hsien Lai, BS, Grace Liu, Laura Rassenti, PhD, Michael Y. Choi, MD, Stephen B Howell, MD, Malcolm Finlayson, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5303.
https://doi.org/10.1182/blood.V122.21.5303.5303
Published: 2013